DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» PCSK9
PCSK9
Human Proprotein Convertase 9/PCSK9 Quantikine
PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different
PCSK9 Inhibitor Non-Response in a Patient with Preserved LDL Receptor
Human Pcsk9 (Proprotein Convertase Subtilisin/Kexin Type 9) Elisa
Co-Segregation of PCSK9 Gene I474V Variant with Diabetic And
Variants of PCSK9 Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans
Checklist for Seeking Approval for a PCSK9 Inhibitor
Enhancing the Value of PCSK9 Monoclonal Antibodies by Identifying Patients Most Likely to Benefit
Sortilin: a Protein Involved in Ldl Metabolism and Atherosclerosis
Molecular Basis for LDL Receptor Recognition by PCSK9
Effect of Evolocumab on Lipoprotein(A)
(PCSK9) Inhibitors and Incident Type 2 Diabetes Mellitus
PCSK9 Inhibitors
PCSK9 Inhibitors NOTICE
PRALUENT® (Alirocumab) Injection, for Subcutaneous Use LDL Apheresis
In Silico Insights Into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
PCSK9 Induces a Pro-Inflammatory Response in Macrophages
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Criteria Approval Date: February 24, 2021
Top View
Proprotein Convertase Subtilisin/Kexin Type 9 Gene Variants in Familial Hypercholesterolemia: a Systematic Review and Meta-Analysis
Antihyperlipidemics-PCSK9.Pdf
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Praluent® the First U.S
PCSK9-Gene-Silencing, Cholesterol-Lowering Drug Impresses
Therapeutic Rnai Targeting PCSK9 Acutely Lowers Plasma Cholesterol in Rodents and LDL Cholesterol in Nonhuman Primates
How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?
Lowering Serum Lipids Via PCSK9-Targeting Drugs: Current Advances and Future Perspectives
Polymorphisms of Rs2483205 and Rs562556 in the PCSK9 Gene Are
PCSK9 Inhibitors – Mechanisms of Action
A New Paradigm in Treating LDL Cholesterol: PCSK9 Inhibitors
Proprotein Convertase Subtilisin/Kexin Type 9
Should PCSK9 Inhibitors Be Used in Statin Intolerant Patients?
PCSK9: a Multi-Faceted Protein That Is Involved in Cardiovascular Biology
The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion
Structural Requirements for PCSK9-Mediated Degradation of the Low-Density Lipoprotein Receptor
Pharmacy Medical Necessity Guidelines: PCSK9 Inhibitor Therapy Effective: June 8, 2021
Update on PCSK9 Inhibitors and Statin Intolerance